John Harry Cross III
CIK: 0001806763
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Cross John Harry III
Cross John Harry III (SEC CIK 0001806763) files insider reports with the SEC as Chief Financial Officer of Senti Biosciences, Inc. (SNTI) and Chief Financial Officer of Sonnet BioTherapeutics Holdings, Inc. (SONN).
Signal8 holds 3 ownership filings by Cross John Harry III (1 Form 3, 2 Form 4), filed between Dec 5, 2024 and Mar 11, 2025. Those filings report 2 transactions, from Dec 11, 2023 to Mar 7, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Cross John Harry III's filings is in PRINCETON,, NJ.
Recent filings by Cross John Harry III
Other insiders filing for Senti Biosciences, Inc. (SNTI)
- Rajangam Kanya, Pres. & Chief Med. & Dev. Off.
- Lu Timothy K, CEO
- Baum Bryan Daniel, Director
- Collins James J., Director
- Hsiung Feng, Director
- Schulz Fran, Director